2. UroToday Home
  3. Video Lectures

ASCO 2022

Advanced Prostate Cancer Practice Informing Data Presented at ASCO 2022 - Neeraj Agarwal
January 5, 2023
Details
Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical Administration - Neal Shore
January 5, 2023
Details
Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer - CALYPSO Trial Results - Tom Powles
January 4, 2023
Details
PSMA PET Imaging in Clinical Practice - Thomas Hope & Jeremie Calais
January 3, 2023
Details
The Effect of Metastasis-Directed Therapy (MDT) on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes - Philip Sutera
January 3, 2023
Details
The ORACLE Study: The Efficacy of Combination Systemic Therapies in Patients with Non-Clear Cell Renal Cell Carcinoma - Deepak Kilari
January 3, 2023
Details
Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg
December 6, 2022
Details
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
November 16, 2022
Details
PSMA PET Scan Imaging in Prostate Cancer - Ashley Ross
November 4, 2022
Details
CAR T and Cellular-Based Therapies - Vivek Narayan
October 17, 2022
Details
Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad Sadeghi
October 17, 2022
Details
A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin
October 17, 2022
Details
A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu
October 16, 2022
Details
Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans
October 16, 2022
Details
Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff
October 16, 2022
Details
Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo
October 16, 2022
Details
Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang
October 16, 2022
Details
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
October 16, 2022
Details
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff
October 16, 2022
Details
Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller
October 13, 2022
Details
Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova
August 7, 2022
Details
How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi
August 7, 2022
Details
BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
August 2, 2022
Details
Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis
July 19, 2022
Details
The Association of PSA Response and Overall Survival in Patients with mHSPC in the Phase 3 ARASENS Trial - Fred Saad
July 19, 2022
Details
Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg
July 15, 2022
Details
No Longer ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer, The ARASENS Trial - Cora Sternberg
July 14, 2022
Details
Theranostics in Prostate Cancer Management - The theraP Trial - Michael Hofman
July 10, 2022
Details
email news signup